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Abstract
Pemphigus is a group of autoimmune blistering disorders associated with autoantibod-
ies against the keratinocyte cell surface. Pemphigus has three major variants: pemphigus 
vulgaris (PV), pemphigus foliaceus (PF), and paraneoplastic pemphigus (PNP) which all 
have further subtypes. The variants of pemphigus are classified depending upon the clin-
ical and histological features, immunofluorescence staining pattern, and autoantibody 
profile of the disease. The onset and course of pemphigus appear on the basis of interac-
tion between genetic predisposition and various triggering factors. Pemphigus vulgaris 
is the most commonly seen and representative clinical form of pemphigus. Together with 
clinical manifestations, the histopathological and immunopathological data support the 
diagnosis. As though some pemphigus variants, particularly pemphigus vulgaris and 
paraneoplastic pemphigus, have a mortality risk, early diagnosis is necessary and onset 
of treatment should be promptly initiated. In this chapter, firstly, classification of pem-
phigus is described. After then, clinical features, histopathological and immunopatho-
logical findings, target antigens, etiopathogenesis and comorbidities of each pemphigus 
variant are discussed briefly.
Keywords: pemphigus, pemphigus variants, clinical manifestations, pathogenesis, 
histopathology, immunopathology
1. Introduction
Pemphigus is a distinct organ-specific autoimmune blistering disorder involving skin and 
mucous membranes associated with autoantibodies directed against desmosomes-intercellular 
adhesive molecule complex localized on the keratinocyte cell surface [1–4].
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Pemphigus has three major variants, which are classified depending on the basis of the clini-
cal, histological features, immunofluorescence staining pattern and autoantibody profile of the 
disease including pemphigus vulgaris (PV), pemphigus foliaceus (PF), and paraneoplastic 
pemphigus (PNP), which all have further subtypes. Less frequently seen and newer variants 
of pemphigus include IgA pemphigus (IGAP) and pemphigus herpetiformis (PH) [1–6].
The term “pemphigus” origins from the Greek word “pemphix”, which has a meaning of 
“blister” [1]. It is a chronic potentially life-threating bullous disorder if not treated on time [4, 
7, 8]. The phenotypes of pemphigus represent a complex spectrum with multiple genetic and 
environmental factors playing a role in disease pathogenesis [9, 10].
Together with clinical manifestations, the histopathological and immunopathological data 
support the diagnosis of the disease. The best site for the cutaneous biopsy for the appropriate 
histopathological examination is a fresh (< 24 h) small vesicle or 1/3 of the peripheral portion 
of the blister including the perilesional normal appearing skin. For direct immunofluores-
cence microscopic (DIF) examination, a perilesional normal appearing skin area up to 1 cm 
from a fresh vesicle should be taken and should be transformed in saline or in a cylinder of 
liquid nitrogen in a period lesser than 36 h [11–13].
As though some pemphigus variants, particularly PV and PNP, are potentially life-threaten-
ing diseases, early diagnosis is necessary and early onset of immunosuppressive treatment 
should be promptly initiated [14]. Moreover, some variants of pemphigus may indicate the 
presence of an underlying malignancy [15].
In this chapter, after the classification of pemphigus, firstly, pathogenetic properties and 
mechanism of acantholysis are discussed. After then, the review of pemphigus including the 
epidemiology, clinical features, histopathological and immunopathological findings, target 
antigens, and comorbidities of each pemphigus variant is discussed briefly.
2. The classification of pemphigus
Pemphigus is classified into two major types according to the level of intraepidermal separation 
by the most authors: PV and PF [2, 16, 17]. In the last decades, rarer and newer variants of pem-
phigus have taken part in classification [1, 4, 6], which is described in the following sections.
3. Pathomechanism of pemphigus
The evidence outlines that pemphigus is mediated by pathogenic circulating anti-Desmoglein 
1/3 (Dsg) antibodies, which mediate blister formation [1–6, 16–21]. Previously, it was accepted 
that the presence of anti-Dsg antibodies alone is sufficient for the development of pemphigus 
[22]. According to the compensation hypothesis, the development of pemphigus is based on 
the normal epidermal distribution of Dsg1 and 3 molecules and Dsg1 and 3 antibody profiles 
[2, 16]. However, several reports have been reported pointing the discrepancy between clini-
cal phenotype and autoantibody profile that contradicts with this theory [22–26].
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While the production of pathogenic autoantibodies (Abs) is the key for the development of 
the disease, today it is obvious that many immunological steps are also required prior to the 
antibody induction [3, 22, 27]. Recent studies investigating the role of lymphocytes have dem-
onstrated the role of T cells and B cells in mouse models of pemphigus and patients, revealing 
insights into the mechanisms of autoimmunity [28].
Today, it is obvious that some HLA class II alleles are involved in the activation of Dsg3-
specific CD4+ T cells, which drives the pathogenetic pathways. The epidermal loss of adhe-
sion is induced by pathogenic IgG Abs, which are produced by B cells. HLA-DRB1*04:02 is 
highly prevalent in PV, which provides the recognition of Dsg3 by CD4+ T cells. T cell-depen-
dent B cell activation is critical for the induction of pathogenic IgG Abs [28–31].
Recent studies have also emphasized the important role of T regulatory (reg) cells in the 
development of pemphigus, and it has been concluded that a balance between self-reactive 
lymphocytes and T reg cells may be a key element in determining whether individuals pro-
duce pathogenic Abs and develop pemphigus or not [9, 32, 33].
4. Pemphigus vulgaris
PV is the most commonly seen and representative clinical form of pemphigus with an inci-
dence of 0.1–0.5/100.000 population [1, 2, 7, 13]. The average age at onset is usually at fourth 
and fifth decades, but may occur in the elderly or children. The incidence rate is higher 
among patients with Jewish and Mediterranean ancestry [1, 2, 5, 7, 13]. Various environ-
mental factors such as drugs (captopril, penicillamine), infections (herpes simplex virus, 
Epstein–Barr virus, etc.), pesticides, ultraviolet radiation (UVR), ionizan radiation, thermal 
burns, stress and food containing an allium, phenol, thiol, or urushiol have been reported to 
trigger PV [10, 13, 34].
4.1. Clinical features
Patients with PV may present with only mucosal involvement and some with both mucosal 
and skin involvement [2, 4, 5]. In majority of the patients, oral mucosa is the site of onset, 
while cutaneous involvement usually occurs subsequently. It is most commonly character-
ized by painful erosions, erosions with whitish exudate and erythematous patches usually 
localized on gingiva and buccal mucosa [1, 2, 4, 5, 13] (Figures 1 and 2). The other mucosal 
areas, nasal cavity, larynx (epiglottis, vocal cords), oropharynx, esophagus, vagina, vulva, 
penis, and anus may also be affected [1, 13]. Epistaxis and hoarseness are present owing to 
the involvement of the nose, pharynx, and larynx [1, 13, 35–37]. Genital mucosa is one of the 
frequent sites involved in PV after the oral mucosa [37].
Cutaneous involvement usually follows mucosal lesions by 3 or 4 months [1, 4, 5]. The skin 
lesions cause burning and painful sensation. Cutaneous lesions are characterized by flaccid bul-
lae evolving into painful extensive erosive areas (Figure 3). These blisters appear on the normal 
or erythematous skin, which are fragile, break rapidly, and it is hard to find an unruptured bul-
lae. The Nikolsky sign is present. The bullae in PV can be localized or generalized, and any area 
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of the skin may be involved. The most frequent areas affected are: face, axilla, and scalp, and 
this may be due to the fact that Dsg3 has its highest expression in these areas [1, 2]. Umbilicus 
and/or nail involvement are the other sites that may be affected [2, 4, 5, 13, 38–40]. The presence 
of the nail lesions may be the sign of relapse or recurrence of the disease [40]. Apart from these, 
cases of PV with the involvement of only cutaneous lesions have also been reported [41–43].
4.2. Histopathology
Intraepidermal suprabasal acantholysis and infiltration with predominantly neutrophils and 
eosinophils are observed (tombstone pattern) [2, 5, 13].
4.3. Immunopathology and target antigens
DIF examination shows lace-like IgG deposition with or without C3 on the surface of the kera-
tinocytes in the mid-lower or entire epidermis [2, 5, 12, 13, 16]. Indirect immunofluorescence 
Figure 1. The eroded lesions are seen on the palate, right and left sides of the lower lip.
Autoimmune Bullous Diseases26
(IIF) examination, using a substrate of normal human skin or monkey esophagus, shows circu-
lating antiepithelial IgG and lace-like deposition [2, 4, 5, 12]. Enzyme-linked immunosorbent 
assay (ELISA) is also available in detecting antigens of PV and serves as a tool for assessing the 
disease severity [44, 45]. Target antigens identified in PV are Dsg1 (with a molecular weight 
(MW) of 165 kD) and Dsg3 (MW-130 kD) [2–5, 9]. Desmocollin (Dcs) is another antigen that is 
thought to be responsible in some pemphigus patients [46, 47].
4.4. Associated diseases
Myasthenia gravis (MG) and abnormalities of thymus including benign or malignant thy-
moma and thymic hyperplasia have been reported to be associated with PV [2, 5, 48, 49]. 
Thymic abnormalities may precede or follow the onset of pemphigus. The other common 
disorders that have been reported to be associated with PV are systemic lupus erythematosus 
(SLE), bullous pemphigoid (BP), and PF [48].
Figure 2. The erosions with whitish exudates are seen on the left posterior side of the buccal mucosa.
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5. Pemphigus vegetans
Pemphigus vegetans (P veg) is accepted as the rarest variety of PV comprising of only 1–2% of 
all pemphigus patients. P veg has been reported to occur in all age groups, affecting primarily 
middle-aged females (sex ratio: F/M = 14/3) [50].
Figure 3. The extensive erosions localized on the back of the patient.
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5.1. Clinical features
P veg is characterized by vegetative lesions preferentially affecting intertriginous (axillary, 
inframammarial areas) and periorificial regions [2, 5, 50–52]. The initial course of the disease 
is similar to PV. In the later stages, tumid vegetating, hypertrophic and verrucous lesions 
occur specifically between skin folds [5, 50, 53]. Two subtypes of P veg are recognized. The 
first one is Neumann P veg, which usually begins like PV with easily rupturing vesicles and 
bullae that evolve to form hypertrophic granulating erosions and then vegetating exuding 
masses. The second type is Hallopeau P veg, which is initially characterized by pustular 
lesions that break and gradually evolve into vegetating erosions [5, 50]. Mucosal involvement 
may not always be seen. Involvement of the vermillion border of the lips is the clinical hall-
mark of oral involvement [54]. Nail involvement is rarely described [50]. In P veg, the course 
of the disease is long, with remission and recurrence periods. Hallopeau P veg has a relatively 
benign course, while the Neumann type is often refractory to therapy. One of the frequent 
complications is the development of secondary bacterial infections, and also malnutrition and 
cachexia may coexist to the condition [5, 50].
5.2. Histopathology
Suprabasal acantholysis is present in the earlier stages of P veg similar to PV. In the following 
periods, irregular epidermal hyperplasia, papillomatosis, microabscess composed of eosino-
phils and neutrophils are also seen [2, 5, 50].
5.3. Immunopathology and target antigens
DIF and IIF examination results are indistinguishable from the findings of PV. As P veg is a 
subtype of PV, it is expected to react with the same antigens, Dsg1 and Dsg3 [2, 5, 50]. The 
presence of auto-Abs targeting additional desmosomal proteins including Dsc1, Dsc2, Dsc3 
and periplakin have also been reported [51, 55].
5.4. Associated diseases
There are a few reports of P veg associated with internal malignancies and HIV infection [48, 
50, 56, 57].
6. Pemphigus foliaceus
PF (foliaceus originates from the Latin word folium with a meaning of “leaf”) is the superficial 
form of pemphigus [1, 2, 4, 5]. PF has a universal occurrence and occurs sporadically, while 
the endemic form of PF, called as fogo selvagem (FS) or wild fire (WF), is predominantly seen 
in the rural and tropical regions of Brazil [5, 7, 16, 58, 59]. Another variant of PF, a localized 
form, is called as pemphigus erythematosus (PE) [16, 59]. Sporadic form of PF is most com-
mon in Europe and USA [16].The average age of PF ranges between 40 and 60 years, while 
FS is very often in children, adolescents and young adults. It is usually seen equally in both 
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females and males with a female preponderancy [59, 60]. FS occurs in genetically related 
family members. It has been reported that black fly (Simulium nigrimanum) bites were more 
frequent in patients with FS than in control patients [61, 62]. The authors suggested this vec-
tor or other infectious agents carry a molecule-triggering anti-Dsg1 response through antigen 
mimicry or cross-reactivity [58, 61].
6.1. Clinical features
PF is considered as a more benign form of the disease generally presenting with only cuta-
neous involvement [2, 5, 16, 59]. However, transition from PV to PF or vice versa may be 
observed [63–65]. More rarely, transition to BP has been reported [65]. The primary clinical 
feature of PF is fragile, superficial bullae evolving rapidly to erosive lesions. Nikolsky sign 
is positive. PF usually begins on the trunk, but may also be localized on the face and scalp. 
Sometimes yellowish crusted and scaly erythematous plaques on face and trunk predominate 
the clinical findings resembling the clinical picture of seborrheic dermatitis [2, 5, 16, 59, 66]. In 
FS, the disease usually begins on the head, neck, and seborrheic regions of the skin. The oral 
mucosa, palms of the hands, and plant of the feet are usually spared [59, 66]. In both PF and 
FS, lesions may become confluent and can transform to exfoliative erythroderma [67]. These 
patients should be hospitalized due to the risk of metabolic instability and mortality [1, 16, 
59]. Pain and/or burning sensation may be noted. Unlike PV, there is no oral or other mucosal 
involvement [2, 5, 16, 59]. Mildest form of PF may be misdiagnosed for years [61].
6.2. Histopathology
Histological separation is more superficial than PV and exists along the granular layer. 
Eosinophilic spongiosis may also be seen in very early forms of PF [2, 5, 16, 59].
6.3. Immunopathology and target antigens
DIF and IIF examination findings are identical to the findings of PV [1, 5, 16, 59]. The intensity 
of the fluorescent stain is greater in the upper epidermis. Dsg1 is the specific target antigen [59].
6.4. Associated diseases
PF may be associated with MG and thymoma [2, 5, 16, 48]. A few cases of coexistence of PF 
with psoriasis [68, 69], malignancy [70, 71] and Graves’ disease [72] have been reported. There 
also a few reports regarding cases of UVR and radiotherapy-induced PF [59, 73, 74].
7. Pemphigus erythematosus
PE, also known as Senear-Usher syndrome, is a localized form of PF [2, 5, 16, 59]. It affects 
most frequently elderly population. Clinical and immunological features of PE resemble both 
PF and cutaneous lupus erythematosus (LE) [16, 75]. Clinically erythematous plaques, scaly 
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to crusted lesions, occur across the malar areas of the face in a butterfly distribution mimick-
ing the clinical appearance of LE [16]. The lesions are usually induced by UVR [75]. In 80% of 
the patients, antinuclear antibodies (ANA) without the presence of anti-ds-DNA antibodies 
may be detected [1, 2, 5, 16, 59]. DIF examination of the lesions may show both intercellular 
(IC) deposition IgG/C3 and granular deposition of IgG and C3 at the dermoepidermal junc-
tion (lupus band test) [5, 16, 59, 75].
8. Paraneoplastic pemphigus
PNP is a rare disease that manifests with clinically distinct painful mucosal erosions and poly-
morphic cutaneous lesions [1, 4, 15, 76]. The incidence of PNP is thought to be less common 
than PV or PF. PNP presents most often in older patients aged between 45 and 70 years [77, 
78]. In almost all cases, PNP is associated with neoplasms mostly with lymphoproliferative 
diseases [4, 15, 66, 76–78].
8.1. Clinical features
The onset of the lesions usually presents with initially limited cheilitis and/or ulcerative 
stomatitis, which then progresses to severe, intractable, hemorrhagical stomatitis with per-
sistent painful mucosal ulcerations in the oropharynx and esophagus [4, 5, 15, 16, 77]. Oral 
lesions usually extend to the vermillion border of the lips [15, 77]. Eye involvement especially 
includes conjunctival erosions and occurs in 70% of patients [79–82]. Cutaneous lesions are 
usually seen after the onset of mucosal involvement with a duration of days to months [77, 
83, 84]. Cutaneous lesions are widespread and are usually polymorphic including lichenoid 
lesions, erythema multiforme-like lesions, vesiculobullous and erosive lesions. The palmar 
involvement is usually observed [4]. Lichen planus-like lesions localized on skin, nails and/or 
mucosa resemble lichen planus, target-like lesions resemble erythema multiforme, and bul-
lous lesions and erosive lesions resemble PV and bullous pemphigoid [4, 15, 66, 76, 77, 83–87]. 
Cutaneous lesions mimicking graft versus host disease or Stevens-Johnson syndrome may 
also be observed [86, 87].
As though most of the patients with PNP are associated with malignancies, the prognosis 
of PNP is severe with a high mortality rate [15, 77, 83, 84, 88, 89]. Internal organ involve-
ment including lungs (Bronchiolitis obliterans), thyroid, kidney and gastrointestinal system 
has been documented [15, 88, 89]. Most authors have reported that the term “paraneoplastic 
pemphigus” is too restrictive to describe the developing multiorgan syndrome involvement 
and have suggested a new nomenclature named as paraneoplastic autoimmune multiorgan 
syndrome (PAMS) [15, 88].
8.2. Histopathology
Several biopsies are often required to achieve the diagnosis [77, 81]. The histopathological 
features of PNP reveal variability according to the type of the morphology of the cutaneous 
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lesion [15, 77, 84, 90]. Intraepidermal suprabasal acantholysis (resembling PV), keratinocyte 
necrosis and vacuolar interface changes (resembling erythema multiforme/lichen planus) 
may be observed [77, 90].
8.3. Immunopathology and target antigens
DIF examination is characterized by the deposition of immunoreactants (IgG deposits with or 
without compleman) in IC region of epidermis and deposition of IgG/IgM and/or C3 along the 
basal zone membrane (BZM) [15, 17, 77, 84]. IIF using rat bladder epithelium as substrate shows 
an IC pattern that appears to be highly specific but less sensitive for PNP/PAMPS (including 
monkey esophagus (86% sensitivity) and murine tongue (100% sensitivity). A variety of antigens 
including Dsg1, Dsg3, envoplakin, periplakin, bullous pemphigoid antigen1 (BPAG1), plectin, 
desmoplakin 1, and desmoplakin 2 can be detected by immunoprecipitation [15, 17, 77, 84].
8.4. Associated diseases
PNP usually precedes the diagnosis of the underlying malignancy. In 1/3 of the cases, the under-
lying malignancy has not been diagnosed at the time of diagnosis. Therefore, when a diagnosis 
of PNP is made, a comprehensive workup for an underlying malignancy is mandatory [4, 15, 
76, 77]. Hematological malignancies are associated with 84% of the patients of PNP. The most 
common reported hematological malignancies are non-Hodgkin lymphoma (38.6%), chronic 
lymphocytic leukemia (18.4%), Castleman disease (18.4%), and thymoma (5.5%) [15, 48, 77, 84].
9. Pemphigus herpetiformis
PH is a rare and distinct entity of pemhigus [6, 11]. It has been first described in patients who 
had clinical features that resemble dermatitis herpetiformis, but showed the features of pem-
phigus histopathologically and immunologically [6, 11, 91, 92]. It usually accounts 6–7% of 
cases and affects females and males equally [11, 92].
9.1. Clinical features
Patients usually have erythematous, gyrate, annular and polycyclic lesions with clusters of 
pustules, vesicles, in herpetiform pattern. The clinical presentation of PH may be atypical and 
may mimic various other bullous diseases [6, 92]. Pruritus is usually present [6, 11, 92, 93]. 
Mucous involvement is not a usual finding [6, 11]. PH usually has a good psis, although some 
cases may progress into classic pemphigus [11, 94].
9.2. Histopathology
The histopathological examination shows eosinophilic or neutrophilic spongiosis and micro-
abscesses (neutrophils and/or eosinophils) in the mid or subcorneal epidermis mostly without 
acantholysis. Acantholysis may be seen in the later stages of the disease process and may be 
minimal [6, 11, 92, 93].
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9.3. Immunopathology and target antigens
DIF examination shows IC deposits of IgG and C3 in epidermis, while IIF examination shows 
circulating IgG auto-Abs. The target antigen is usually Dsg 1 (or less frequently Dsg3) [6, 11, 
95]. Recent studies have demonstrated DSc1, Dsc3 and unknown protein 178-kDa protein [11, 
92, 96] by immunoblotting.
9.4. Associated diseases
There is evidence of association of PH with some diseases such as SLE, autoimmune hemo-
lytic anemia and psoriasis and with some malignancies (prostate, esophagus) in the literature 
[11, 97–101].
10. IgA pemphigus
IGAP is a rare entity of pemphigus [6, 11]. It has two clinical types: intraepidermal neutro-
philic type (IEN) and subcorneal pustular dermatosis (SPD) [6, 11, 66]. It is usually observed 
in the middle-aged or the elderly with an average age at 48 years, but also has been reported 
in childhood [6, 11]. There is a slight predominance of females [6].
10.1. Clinical features
Patients with both types of IGAP present with flaccid vesicles or pustules on either ery-
thematous or normal skin mostly localized on axillary and groin areas, but trunk, proximal 
extremities and abdominal regions are also involved. The pustules tend to coalesce to form 
annular or circinate pattern. SPD is clinically indistinguishable from the disease subcorneal 
pustular dermatosis. In IEN type, pustules coalesce to form a sunflower-like configuration 
[2, 6, 11, 102, 103]. Pruritus is severe and affects patients’ daily activities. Mucosal involve-
ment is rare [2, 6, 11].
10.2. Histopathology
There is slight acantholysis and neutrophilic infiltration in epidermis. In SPD type, neutro-
philic infiltration is localized subcorneally in the upper epidermis, while in IEN type in lower 
epidermis or entire epidermis [5, 6, 11].
10.3. Immunopathology and target antigens
In DIF examination, deposition of IgA in IC space of epidermis is detected. IgG and/or C3 
is sometimes deposited but is weaker than IgA. In the SPD type, deposition is limited to 
upper epidermis, while in IEN type, it is deposited in lower epidermis or in whole epider-
mis [6, 11]. Using healthy human skin and monkey esophagus, circulating IgA auto-Abs 
have been demonstrated in 50% of the patients [5, 11]. The antigens in IGAP are Dsg1, Dsg3, 
Dsc1, and Dsc3 [3, 4]
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10.4. Associated diseases
In SPD type, the most frequently reported association is monoclonal IgA gammopathy [11, 
48, 103]. The skin symptoms may precede monoclonal IgA or may be detected during the 
disease course [104]. The other associated diseases are multiple myeloma, lymphoma, Crohn 
disease, and ulcerative colitis [48, 103, 104].
11. Conclusion
Pemphigus, especially some types, is a life-threatening disease and has a mortality risk. Therefore, 
the diagnosis should be made as soon as possible, and the treatment should be started. Today, 
a better understanding of the role of immunological dysregulation in the pathogenesis will also 
cause offering newly targeted therapeutical agents in the treatment of pemphigus.
Abbreviations
Abs   Antibodies
ACE  Angiotensin-converting enzyme
ANA  Antinuclear antibody
Anti-ds DNA Double-stranded DNA antibody
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P veg  Pemphigus vegetans
PAMPS  Paraneoplastic autoimmune multi-organ syndrome
PE  Pemphigus erythematosus
PF  Pemphigus foliaceus
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PV  Pemphigus vulgaris
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